S&P 500

5.431,60

-0,04%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
DMK Pharmaceuticals Corporation (DMK)
DMK Pharmaceuticals Corporation (DMK) Notícias

DMK

DMK Pharmaceuticals (DMK)

DMK Pharmaceuticals Corporation

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:DMK

1

Data	Hora	Fonte	Título	Código	Companhia
21/03/2024	15:23	Edgar (US Regulatory)	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
07/02/2024	19:19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
06/02/2024	12:04	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:DMK	DMK Pharmaceuticals Corporation
23/01/2024	19:23	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
21/12/2023	10:15	GlobeNewswire Inc.	DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI	NASDAQ:DMK	DMK Pharmaceuticals Corporation
28/11/2023	10:05	GlobeNewswire Inc.	DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update	NASDAQ:DMK	DMK Pharmaceuticals Corporation
14/11/2023	09:30	GlobeNewswire Inc.	DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:DMK	DMK Pharmaceuticals Corporation
13/11/2023	12:52	GlobeNewswire Inc.	DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023	NASDAQ:DMK	DMK Pharmaceuticals Corporation
02/11/2023	17:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
02/11/2023	17:31	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
30/10/2023	08:30	GlobeNewswire Inc.	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:DMK	DMK Pharmaceuticals Corporation
19/10/2023	17:05	GlobeNewswire Inc.	DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth	NASDAQ:DMK	DMK Pharmaceuticals Corporation
17/10/2023	13:28	Edgar (US Regulatory)	Form PX14A6G - Notice of exempt solicitation submitted by non-management	NASDAQ:DMK	DMK Pharmaceuticals Corporation
12/10/2023	17:22	Edgar (US Regulatory)	Form DEFC14A - Definitive proxy statement, contested solicitations	NASDAQ:DMK	DMK Pharmaceuticals Corporation
02/10/2023	17:49	Edgar (US Regulatory)	Form PREC14A - Preliminary proxy statements, contested solicitations	NASDAQ:DMK	DMK Pharmaceuticals Corporation
26/09/2023	09:37	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:DMK	DMK Pharmaceuticals Corporation
07/09/2023	13:00	GlobeNewswire Inc.	Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus	NASDAQ:DMK	DMK Pharmaceuticals Corporation